IP Verse

(+)-2-[1-(3-Ethoxy-4-Methoxyphenyl)-2-Methylsulfonylethyl]-4-Acetylaminoisoindoline-1,3-Dione: Methods Of Using And Compositions Thereof

Patent No. EP2223688 (titled "(+)-2-[1-(3-Ethoxy-4-Methoxyphenyl)-2-Methylsulfonylethyl]-4-Acetylaminoisoindoline-1,3-Dione: Methods Of Using And Compositions Thereof") was filed by Amgen Europe on Mar 20, 2003. The application was issued on May 29, 2019.

Patent Summary

Patent Family

Patent Family

Patent Oppositions (5)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentative
GALENICUM HEALTH SLUMar 2, 2020-
HEXALFeb 28, 2020TER MEER STEINMEISTER & PARTNER
HOFFMANN EITLEFeb 28, 2020-
ZENTIVA KSFeb 28, 2020HOFFMANN EITLE
WUESTHOFF & WUESTHOFF PATENTANWALTE PARTG MBBFeb 26, 2020SONNENHAUSER

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents

EP2223688

AMGEN EUROPE
Application Number
EP10162667A
Filing Date
Mar 20, 2003
Status
Revoked
Jan 21, 2022
Publication Date
May 29, 2019
External Links
Slate, Register , Google Patents